Hone Health announced the raising of $228 million to develop its physician-managed longevity platform and personalized medical services. In this round, the company secured $28 million in equity capital and $200 million in growth capital.
Marcy Pen Capital Partners played a leading role in the Series A extension round. This venture firm was previously the lead investor in Hone's undisclosed Series A round. The $200 million funding was provided by the Customer Value Fund from General Catalyst, as well as numerous private investors.
Hospitality entrepreneur David Grattman joined as a strategic investor and advisor. Investors also included Nick Jonas, Joe Jonas, Kevin Jonas, Marcello Hernandez, and Kelly Rowland. These funding rounds provide Hone with a total of $65 million in equity capital.
The funds will be directed towards expanding clinical care, implementing new diagnostic methods, clinical technologies, new therapies, and research. Furthermore, plans include developing physician-curated programs in metabolism, PCOS, inflammation, and immunity. Hone will also offer new diagnostic services to help patients better understand various aspects of their long-term health.
The company plans to introduce updates, including whole-body MRI, DEXA scanning, coronary CT angiography, and gut microbiome testing. Hone will also add physician-led peptide programs. The company aims to integrate this data with existing patient data to gain a more complete picture of individual health trends. The system integrates laboratory test results, medical history, current symptoms, and medication information.
In addition to securing funding, Hone today launched Hone Black publicly. This concierge-style membership program was previously in soft launch for selected patients. The program combines comprehensive diagnostic testing with continuous medical monitoring. All participants undergo testing across more than 1600 health metrics, and patients receive support from a team of physicians managing all bodily care. Treatment plans include prescription medications, supplements, peptides, and lifestyle coaching. The program also includes exosome and stem cell therapies. Hone Black represents the company's approach to providing personalized care outside of consultations, integrating diagnostic information with ongoing medical relationships.
Hone claims to have served over 200,000 patients, conducted 750,000 tests, and analyzed 25 million health metrics. Co-founder and CEO Saad Alam stated that the funding will allow Hone to scale its products into other therapeutic classes.
Hone's new funding comes amid growing demand for preventive medicine. According to the company, people are striving to take control of their health before problems arise, citing a survey where 89% of women expressed a desire to be more proactive about their health. It was also noted that personal care and nutrition accounted for over 90% of consumer health spending in 2025. The £33 million Series A round announced by Hone in January 2025 will help the business move beyond hormone optimization into other areas of longevity. Since then, the company has expanded into other medical fields, including cardiovascular care programs using biomarker analysis and Prenuvo whole-body scanning, as well as DEXA Body Spec scanning. The new funding will provide Hone with capital to develop its technology platform and clinical network.



